Skip to main content

Vaxart, Inc. (VXRT)

NASDAQ: VXRT · IEX Real-Time Price · USD
6.56
0.21 (3.31%)
At close: Dec 8, 2021 4:00 PM
6.59
0.03 (0.46%)
After-hours:Dec 8, 2021 7:59 PM EST
Market Cap823.25M
Revenue (ttm)1.17M
Net Income (ttm)-63.57M
Shares Out125.50M
EPS (ttm)-0.54
PE Ration/a
Forward PE45.87
Dividendn/a
Ex-Dividend Daten/a
Volume2,066,550
Open6.35
Previous Close6.35
Day's Range6.09 - 6.64
52-Week Range4.86 - 24.90
Beta0.34
AnalystsStrong Buy
Price Target13.00 (+98.2%)
Earnings DateNov 11, 2021

About VXRT

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, wh...

IndustryBiotechnology
Employees28
Stock ExchangeNASDAQ
Ticker SymbolVXRT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Vaxart stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 98.17% from the latest price.

Price Target
$13.00
(98.17% upside)
Analyst Consensus: Strong Buy

News

Why Shares of Pfizer, Ocugen, and Vaxart Are Losing Ground Today

The initial data on omicron suggests that the pandemic has entered a new, less deadly phase.

Other symbols:OCGNPFE
2 days ago - The Motley Fool

VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just Sent Vaxart Down

Despite a new factory acquisition, VXRT stock is down 9% on the day as 'Mad Money' host Jim Cramer warns investors about Vaxart. The post VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just...

1 week ago - InvestorPlace

Vaxart Announces Acquisition of Second GMP Manufacturing Facility

Purchase expected to give Vaxart greater control over manufacturing schedules Purchase expected to give Vaxart greater control over manufacturing schedules

1 week ago - GlobeNewsWire

Vaxart Stock Breaks Out Of Pennant Pattern: Now What?

Vaxart Inc. (NASDAQ:VXRT) shares were trading higher Monday. A company executive will present an overview of the company's COVID-19 oral vaccine candidate at the World Vaccine & Immunotherapy Congress o...

1 week ago - Benzinga

Why Vaxart Stock Is About Ready To See A Breakout

Vaxart Inc. (NASDAQ:VXRT) shares are trading higher Wednesday.  The company announced that an executive will present an overview of the company's COVID-19 oral vaccine candidate at the World Vaccine & I...

2 weeks ago - Benzinga

3 Vaccine Latecomers That Could Double Your Money

Catalysts for the stocks are just ahead.

Other symbols:GRTSINO
2 weeks ago - The Motley Fool

Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine...

A new Stanford study published in Cell Host and Microbe finds that protection against influenza infection may be achieved through mechanisms other than the development of serum antibodies A new Stanford...

2 weeks ago - GlobeNewsWire

Vaxart Stock Is Being Squeezed At The End Of A Pattern

Vaxart Inc. (NASDAQ:VXRT) shares are trading higher Thursday after bouncing off support. There looks to be no company evident news to explain the jump in price.

2 weeks ago - Benzinga

Vaxart to Participate at Upcoming Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and CEO, Dr. Sean Tucker, SVP and Chief Scientific Officer, and ...

3 weeks ago - GlobeNewsWire

3 COVID Pill Stocks That Might Be Game-Changers

Only two of the pills are slated to be therapeutic.

Other symbols:MRKPFE
1 month ago - The Motley Fool

VAXART, INC. (VXRT) Reports Q3 Loss, Lags Revenue Estimates

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 6.67% and -9.91%, respectively, for the quarter ended September 2021.

1 month ago - Zacks Investment Research

Earnings Preview: VAXART, INC. (VXRT) Q3 Earnings Expected to Decline

VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 month ago - Zacks Investment Research

Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results

Four clinical trials for COVID-19 and norovirus oral tablet vaccine candidates are currently ongoing

1 month ago - GlobeNewsWire

5 Biotech Stocks With 105% to 386% Upside, According to Wall Street

Based on analysts' loftiest price targets, these drugmakers could double to nearly quintuple investors' money over the next 12 months.

Other symbols:CRSPICPTLGNDNVAX
1 month ago - The Motley Fool

Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced that it has dosed the first subject in its Phase II COVID-19 oral tablet vaccine clinical trial, th...

1 month ago - PRNewsWire

Don't Write Off Vaxart, As Its Oral Vaccine Still Has a Chance

VXRT stock is still worth a shot, as there's still big potential demand for a "no-needle" Covid-19 vaccine alternative. The post Don't Write Off Vaxart, As Its Oral Vaccine Still Has a Chance appeared f...

1 month ago - InvestorPlace

Can This COVID Vaccine Stock Help Make You Rich?

This biotech has a nifty trick potentially up its sleeve.

1 month ago - The Motley Fool

Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up

Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesday after the Indian government approved Bharat Biotech's COVID-19 vaccine Covaxin, for children between the ages of 2 and 18. Ocugen is partnere...

Other symbols:MRNANVAXOCGN
1 month ago - Benzinga

Vaxart May Be a COVID Vaccine Game Changer -- but Is It Too Late?

The company is working on a vaccine candidate that doesn't involve a needle.

1 month ago - The Motley Fool

Why Vaxart Shares Are Trading Higher Today

Vaxart Inc (NASDAQ: VXRT) is trading higher Friday after the company reported a Duke University-led study published in bioRxiv showed that the company's investigational oral tablet vaccine reduced the a...

2 months ago - Benzinga

These 2 COVID-19 Stocks Could Boost the Market Friday

Thursday's gains could be just the beginning.

Other symbols:QDEL
2 months ago - The Motley Fool

Why Vaxart Shares Are Surging In Thursday's After-Hours Session

Vaxart Inc (NASDAQ: VXRT) is surging higher in after-hours trading Thursday after the company reported a Duke University-led study published in bioRxiv showed that the company's investigational oral tab...

2 months ago - Benzinga

New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SA...

SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 /PRNewswire/ -- A Duke University-led study published in bioRxiv showed that Vaxart, Inc.'s (NASDAQ: VXRT) investigational oral tablet vaccine reduced the airbo...

2 months ago - PRNewsWire

Vaxart (VXRT) Starts Recruitment in Oral COVID-19 Vaccine Study

Vaxart (VXRT) commences recruiting subjects in its mid-stage study for its oral vaccine tablet for COVID-19. It will begin dosing in the United States later this month.

2 months ago - Zacks Investment Research

Why Vaxart Stock Tumbled in September

A COVID-19 antiviral pill may undermine the biotech's value proposition.

2 months ago - The Motley Fool